Novo Nordisk A/S
Denmark · DK0060534915 · reports in DKK · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue +6.4% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Good
- It earned 53% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Fair
- Equity is 36% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in DKK.
DKK 309.1B
revenue
41%
operating margin
DKK 102.4B
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | DKK 177.0B | DKK 232.3B | DKK 290.4B | DKK 309.1B |
| Operating profit | DKK 74.8B | DKK 102.6B | DKK 128.3B | DKK 127.7B |
| Earnings per share | DKK 12.26 | DKK 18.67 | DKK 22.67 | DKK 23.06 |
| Cash from operations | DKK 78.9B | DKK 108.9B | DKK 121.0B | DKK 119.1B |
| Capital spending | DKK 12.1B | DKK 25.8B | DKK 47.2B | DKK 60.1B |
| Cash | DKK 12.7B | DKK 14.4B | DKK 15.7B | DKK 26.5B |
| Total assets | DKK 241.3B | n/a | DKK 465.6B | DKK 542.9B |
| Equity | DKK 83.5B | DKK 106.6B | DKK 143.5B | DKK 194.0B |
What they do
In the company's own words, from the annual report.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.